Dublin, May 24, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Systemic Lupus Erythematosus (SLE) Market and Forecast Analysis" report to their offering.
Lupus is a chronic inflammatory autoimmune disorder that can affect many different body systems, including the joints, skin, kidneys, blood cells, brain, heart, and lungs. Systemic lupus erythematosus refers to the systemic form of the disease, which includes organ-specific variants, such as lupus nephritis.
This disorder can be very difficult to diagnose as its signs and symptoms often mimic those of other conditions, and a physician is unlikely to ever see two cases that are alike. The most concerning symptoms are the ones that do not currently respond well to treatment, including renal and neurologic symptoms, as these can cause severe morbidity, disability, and ultimately fatal outcomes.
Benlysta (belimumab; GlaxoSmithKline) became the first new therapy for lupus in over 50 years when it gained approval in 2011. However, despite significant hype surrounding its launch, uptake has been low, and the market remains open and eager for effective targeted therapies.
Key Topics Covered:
1. Forecast: Systemic Lupus Erythematosus
- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- anifrolumab
- Benlysta SLE (belimumab)
- blisibimod
- Primary Research Methodology
2. Epidemiology: Systemic Lupus Erythematosus
- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
- Appendix: Additional Sources
3. Marketed Drugs: Systemic Lupus Erythematosus
- Executive Summary
- Product Overview
- Primary Research Methodology
- Product profile: Benlysta
- Product profile: Off-label: CellCept
- Product profile: Off-label: Rituxan
4. Pipeline: Systemic Lupus Erythematosus
- Executive Summary
- Clinical Pipeline Overview
- Comparator Therapy
- Clinical Trial Design
- Recently Discontinued Drugs
- Product profile (late stage): Lupuzor
- Product profile (late stage): Orencia
- Product profile (late stage): anifrolumab
- Product profile (late stage): atacicept
- Product profile (late stage): blisibimod
For more information about this report visit http://www.researchandmarkets.com/research/79djqh/systemic_lupus